azathioprine has been researched along with cladribine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Becker, CC; Fleming, JO; Gidal, BE | 1 |
| Schmied, M; Vass, K | 1 |
| McCune, WJ; Singer, NG | 1 |
| Bryant, J; Clegg, A; Milne, R | 1 |
| Callen, JP | 1 |
| Bryant, J; Clegg, A | 1 |
| Lublin, FD | 1 |
| Heath, M; Raugi, GJ | 1 |
| Robak, E; Sysa-Jedrzejowska, A; Wozniacka, A | 1 |
| Schmidt, S | 1 |
| Christensen, E; Rowinski, SA | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Benedetti, MD; Capobussi, M; Castellini, G; Featherstone, R; Filippini, G; Frau, S; Gonzalez-Lorenzo, M; Lucenteforte, E; Perduca, V; Tramacere, I; Virgili, G | 1 |
13 review(s) available for azathioprine and cladribine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Immunotherapy in multiple sclerosis, Part 2.
Topics: Adult; Azathioprine; Cladribine; Clinical Trials as Topic; Cyclophosphamide; Cyclosporins; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Immunotherapy; Interferons; Multiple Sclerosis; Peptides; Randomized Controlled Trials as Topic; Time Factors | 1995 |
[Current therapy of multiple sclerosis].
Topics: Azathioprine; Cladribine; Cyclophosphamide; Glatiramer Acetate; Humans; Interferon-beta; Methotrexate; Mitoxantrone; Multiple Sclerosis; Peptides; Plasmapheresis; Randomized Controlled Trials as Topic | 1996 |
Update on immunosuppressive therapy.
Topics: Adult; Arthritis, Juvenile; Azathioprine; Behcet Syndrome; Child; Cladribine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Granulomatosis with Polyangiitis; Humans; Hydroxychloroquine; Immunosuppressive Agents; Liver; Lung; Lung Injury; Lupus Erythematosus, Systemic; Methotrexate; Pemphigoid, Benign Mucous Membrane; Retina; Tacrolimus; Thalidomide | 1998 |
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Topics: Adjuvants, Immunologic; Azathioprine; Cladribine; Cost-Benefit Analysis; Cyclophosphamide; Drug Costs; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-beta; Methotrexate; Mitoxantrone; Multiple Sclerosis; Peptides; Research Design; Technology Assessment, Biomedical; Treatment Outcome | 2000 |
Immunosuppressive and cytotoxic drugs in the treatment of rheumatic skin disorders.
Topics: Adult; Alkylating Agents; Antimetabolites; Azathioprine; Child; Chlorambucil; Cladribine; Cyclophosphamide; Cyclosporine; Drug Interactions; Female; Humans; Immunosuppressive Agents; Methotrexate; Mycophenolic Acid; Pregnancy; Pregnancy Complications; Rheumatic Diseases; Skin Diseases; Thioguanine | 2001 |
Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.
Topics: Azathioprine; Cladribine; Cost-Benefit Analysis; Cyclophosphamide; Drug Costs; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-beta; Methotrexate; Mitoxantrone; Multiple Sclerosis; Peptides | 2001 |
Therapeutic approaches to secondary progressive multiple sclerosis.
Topics: Anti-Inflammatory Agents; Azathioprine; Bone Marrow Transplantation; Cladribine; Clinical Trials as Topic; Cyclosporine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Methotrexate; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Chronic Progressive | 2002 |
Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimalarials; Azathioprine; Cladribine; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Humans; Immunoglobulin G; Immunologic Factors; Immunotherapy; Isoxazoles; Leflunomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Rituximab; Tacrolimus; Thalidomide | 2004 |
[Progress and perspectives in the treatment of systemic lupus erythematosus].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antineoplastic Agents, Alkylating; Azathioprine; Cladribine; Cyclophosphamide; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mycophenolic Acid; Vidarabine | 2005 |
[Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Animals; Azathioprine; Cladribine; Clinical Trials, Phase III as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Infusions, Intravenous; Long-Term Care; Lymphopenia; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neoplasms; Pregnancy; Purine Nucleosides; Randomized Controlled Trials as Topic; Thrombocytopenia | 2010 |
Epidemiologic and therapeutic aspects of refractory coeliac disease - a systematic review.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Celiac Disease; Cladribine; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Mesalamine; Prednisolone; Prevalence; Thioguanine | 2016 |
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Topics: Adolescent; Adult; Alemtuzumab; Azathioprine; Cladribine; Daclizumab; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Immunotherapy; Interferon beta-1a; Interferon beta-1b; Male; Multiple Sclerosis; Natalizumab; Network Meta-Analysis; Rituximab; Young Adult | 2023 |
6 other study(ies) available for azathioprine and cladribine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |